How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
58
CDTX Quote, Financials, Valuation and Earnings
Last price:
$221.38
Seasonality move
:
-12.24%
Day range:
$221.38 - $221.38
52-week range:
$15.22 - $221.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
55.23x
P/B ratio:
16.48x
Volume:
--
Avg. volume:
286.8K
1-year change:
942.77%
Market cap:
$7B
Revenue:
$1.3M
EPS (TTM):
-$11.78
Analysts' Opinion
-
Consensus RatingCidara Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $221.50, Cidara Therapeutics, Inc. has an estimated upside of 0.05% from its current price of $221.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $221.50 representing 100% downside risk from its current price of $221.38.
Fair Value
-
According to the consensus of 3 analysts, Cidara Therapeutics, Inc. has 0.05% upside to fair value with a price target of $221.50 per share.
CDTX vs. S&P 500
-
Over the past 5 trading days, Cidara Therapeutics, Inc. has overperformed the S&P 500 by 0.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cidara Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cidara Therapeutics, Inc. revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Cidara Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Cidara Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cidara Therapeutics, Inc. reported earnings per share of -$3.10.
Enterprise value:
6.5B
EV / Invested capital:
--
Price / LTM sales:
55.23x
EV / EBIT:
--
EV / Revenue:
80.13x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-49.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$163K
Return On Assets:
-56.95%
Net Income Margin (TTM):
-185.55%
Return On Equity:
-68.74%
Return On Invested Capital:
-68.01%
Operating Margin:
-3675.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $50.6M | $4M | -- | -- | -- | |
| Gross Profit | $50.5M | $3.8M | -$163K | -$61K | -$28K | |
| Operating Income | -$21.9M | -$45.7M | -$159.9M | -$17.4M | -$43.6M | |
| EBITDA | -$21.8M | -$45.5M | -$159.7M | -$17.3M | -$43.6M | |
| Diluted EPS | -$8.35 | -$25.02 | -$11.78 | -$2.45 | -$3.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $47.3M | $63.9M | $57.7M | $156.8M | $442.8M | |
| Total Assets | $51.2M | $66.9M | $63.5M | $162.3M | $518.7M | |
| Current Liabilities | $33.5M | $33M | $35.6M | $44.3M | $95.8M | |
| Total Liabilities | $52.4M | $57.8M | $55.4M | $46.7M | $96.3M | |
| Total Equity | -$1.2M | $9.1M | $8M | $115.6M | $422.4M | |
| Total Debt | $5.3M | $344K | $3.3M | $2.6M | $424K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.7M | -$159.8M | -$132.9M | -$36.7M | -$40.6M | |
| Cash From Investing | -$336K | -$307K | -$176.3M | -$106K | -$176.5M | |
| Cash From Financing | $26.6M | $238.9M | $481.8M | -$182K | $160K | |
| Free Cash Flow | -$31M | -$160.1M | -$132.9M | -$36.8M | -$40.6M | |
CDTX
Sector
Market Cap
$7B
$23.4M
Price % of 52-Week High
99.98%
48.49%
Dividend Yield
0%
0%
Shareholder Yield
-17.14%
-1.67%
1-Year Price Total Return
942.77%
-23.18%
Beta (5-Year)
1.561
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$221.38
200-day SMA
Buy
Level
$104.87
Bollinger Bands (100)
Buy
Level
103.7 - 228.24
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$221.38
Relative Strength Index (RSI14)
Buy
Level
84.21
ADX Line
Neutral
Level
Williams %R
Sell
Level
-18.75
50-day SMA
Buy
Level
$220.84
MACD (12, 26)
Buy
Level
60.42
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.0852)
Sell
CA Score
(Annual)
Level (-3.1464)
Buy
Beneish M-Score
(Annual)
Level (-5.5073)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.0335)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, CDTX has received 0 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CDTX average analyst price target in the past 3 months is $221.50.
-
Where Will Cidara Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cidara Therapeutics, Inc. share price will rise to $221.50 per share over the next 12 months.
-
What Do Analysts Say About Cidara Therapeutics, Inc.?
Analysts are divided on their view about Cidara Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cidara Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $221.50.
-
What Is Cidara Therapeutics, Inc.'s Price Target?
The price target for Cidara Therapeutics, Inc. over the next 1-year time period is forecast to be $221.50 according to 3 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CDTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cidara Therapeutics, Inc. is a Hold. 3 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CDTX?
You can purchase shares of Cidara Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cidara Therapeutics, Inc. shares.
-
What Is The Cidara Therapeutics, Inc. Share Price Today?
Cidara Therapeutics, Inc. was last trading at $221.38 per share. This represents the most recent stock quote for Cidara Therapeutics, Inc.. Yesterday, Cidara Therapeutics, Inc. closed at $221.38 per share.
-
How To Buy Cidara Therapeutics, Inc. Stock Online?
In order to purchase Cidara Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CDTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CDTX
Sector
P/E ratio
--
23.40x
PEG ratio
0.00x
-0.01x
P/B ratio
16.48x
1.74x
Price / LTM sales
55.23x
1.48x
Growth Metrics
CDTX
Sector
Revenue growth
-100%
3.36%
Earnings growth
-26.48%
9.35%
Revenue (5-year growth)
-42.85%
6.22%
Earnings forecast
-$1.56
-$0.19
Profitability
CDTX
Sector
Profitability FY 2024
$1M
$2.7M
Return on invested capital
-68.01%
-33.62%
Return on assets
-56.95%
-29.68%
Return on equity
-68.74%
-38.98%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
CDTX
Sector
Total cash
$426.4M
$25M
Short term investments
--
$23.9M
Total assets
$215.6M
$72.5M
Long term debt
$424K
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
